[go: up one dir, main page]

CY1125395T1 - Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες - Google Patents

Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες

Info

Publication number
CY1125395T1
CY1125395T1 CY20211100955T CY211100955T CY1125395T1 CY 1125395 T1 CY1125395 T1 CY 1125395T1 CY 20211100955 T CY20211100955 T CY 20211100955T CY 211100955 T CY211100955 T CY 211100955T CY 1125395 T1 CY1125395 T1 CY 1125395T1
Authority
CY
Cyprus
Prior art keywords
compositions
antimicrobial compositions
effecting
substances
effecting substances
Prior art date
Application number
CY20211100955T
Other languages
English (en)
Inventor
Danping Li
Original Assignee
Melinta Subsidiary Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Subsidiary Corp. filed Critical Melinta Subsidiary Corp.
Publication of CY1125395T1 publication Critical patent/CY1125395T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις, οι οποίες περιλαμβάνουν έναν αντιμικροβιακό παράγοντα παραγώγου του καρβοξυλικού οξέος της κινολόνης και μία αναβράζουσα ουσία. Οι εν λόγω συνθέσεις έχουν βελτιωμένη ανεκτικότητα από το γαστρεντερικό ή/και μειωμένη πιθανότητα να προκαλέσουν παρενέργειες στο γαστρεντερικό. Αυτές οι συνθέσεις είναι χρήσιμες για από του στόματος χορήγηση για τη θεραπευτική αντιμετώπιση, την πρόληψη ή τη μείωση του κινδύνου μικροβιακών λοιμώξεων.
CY20211100955T 2014-06-20 2021-11-04 Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες CY1125395T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014786P 2014-06-20 2014-06-20
PCT/US2015/036605 WO2015196027A1 (en) 2014-06-20 2015-06-19 Antimicrobial compositions with effervescent agents
EP15810507.2A EP3157510B1 (en) 2014-06-20 2015-06-19 Antimicrobial compositions with effervescent agents

Publications (1)

Publication Number Publication Date
CY1125395T1 true CY1125395T1 (el) 2023-03-24

Family

ID=54868661

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100664T CY1121995T1 (el) 2014-06-20 2019-06-26 Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες
CY20211100955T CY1125395T1 (el) 2014-06-20 2021-11-04 Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100664T CY1121995T1 (el) 2014-06-20 2019-06-26 Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες

Country Status (32)

Country Link
US (2) US20150366857A1 (el)
EP (3) EP3919057A1 (el)
JP (2) JP6995479B2 (el)
CN (2) CN106572982B9 (el)
AR (1) AR100920A1 (el)
AU (3) AU2015276954B2 (el)
BR (1) BR112016029761B1 (el)
CA (1) CA2952950C (el)
CL (2) CL2016003273A1 (el)
CR (2) CR20200565A (el)
CY (2) CY1121995T1 (el)
DK (2) DK3157510T3 (el)
EA (1) EA034152B1 (el)
EC (1) ECSP16095540A (el)
ES (2) ES2732865T3 (el)
HR (2) HRP20211685T1 (el)
HU (2) HUE044764T2 (el)
IL (1) IL249622A0 (el)
LT (2) LT3157510T (el)
MX (2) MX368940B (el)
PE (2) PE20210927A1 (el)
PH (2) PH12016502548B1 (el)
PL (2) PL3157510T3 (el)
PT (2) PT3157510T (el)
RS (2) RS62538B1 (el)
SI (2) SI3157510T1 (el)
SM (2) SMT202100618T1 (el)
SV (1) SV2016005349A (el)
TR (1) TR201909417T4 (el)
TW (2) TWI732337B (el)
UY (1) UY36184A (el)
WO (1) WO2015196027A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194617A (en) * 1988-12-17 1993-03-16 Meiji Seika Kaisha, Ltd. 2,3-disubstituted-4-hydroxyquinoline derivatives
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
WO1997011068A1 (fr) 1995-09-22 1997-03-27 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives de l'acide pyridone-carboxylique ou leurs sels et agent antibacterien les contenant comme ingredient actif
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
UA73287C2 (en) 1998-09-14 2005-07-15 Ranbaxy Lab Ltd Ciprofloxacin formulation with delayed release
US6187317B1 (en) * 1999-07-14 2001-02-13 Judith Taylor Natural anti-diarrheal composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
MX2007001134A (es) 2004-07-30 2007-04-17 Abbott Lab Preparacion de antibacterianos de acido piridonacarboxilico.
DK3056492T3 (da) * 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)
BRPI0517891A (pt) * 2004-11-24 2008-10-21 Medpointe Healthcare Inc composições compreendendo azelastina e métodos de uso das mesmas
RS52354B (en) 2005-04-11 2012-12-31 Abbott Laboratories PHARMACEUTICAL MIXTURES WHICH HAVE ADVANCED DISSOLUTION PROFILES FOR Slightly Soluble Medicines
DE602005007205D1 (de) 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US7736485B2 (en) * 2006-08-11 2010-06-15 Aqua Resources Corporation Nanoplatelet magnesium hydroxides and methods of preparing same
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
NZ578204A (en) 2006-12-22 2012-05-25 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
AU2008258596B2 (en) * 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EA025637B1 (ru) * 2008-11-15 2017-01-30 Мелинта Терапьютикс, Инк. Противомикробные композиции
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
EP3581574A1 (en) * 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
KR101900249B1 (ko) * 2011-01-14 2018-11-02 스페로 트리넴, 인코포레이티드 자이라제 억제제 （ｒ）­１­에틸­３­［６­플루오로­５­［２­（１­하이드록시­１­메틸­에틸）피리미딘­５­일］­７­（테트라하이드로푸란­２­일）­１ｈ­벤즈이미다졸­２­일］우레아의 고체 형태
JP2013034468A (ja) * 2011-08-10 2013-02-21 Nisshin Sugar Mfg Co Ltd 発泡成型甘味料
US20140328884A1 (en) * 2011-12-16 2014-11-06 Celanese Eva Performance Polymers, Inc. Controlled release vehicles having desired void volume architectures
CN102697751A (zh) * 2012-05-30 2012-10-03 河南牧翔动物药业有限公司 一种畜禽专用恩诺沙星泡腾分散片及其制备方法

Also Published As

Publication number Publication date
AU2021286284B2 (en) 2024-02-29
HUE056298T2 (hu) 2022-02-28
HRP20191133T1 (hr) 2019-09-20
CA2952950A1 (en) 2015-12-23
TR201909417T4 (tr) 2019-07-22
PL3157510T3 (pl) 2019-12-31
BR112016029761A8 (pt) 2021-06-29
NZ727638A (en) 2023-08-25
CR20160592A (es) 2017-02-21
AU2015276954A1 (en) 2017-01-12
PH12016502548A1 (en) 2017-04-10
AU2020256457B2 (en) 2021-09-30
AR100920A1 (es) 2016-11-09
SMT201900348T1 (it) 2019-09-09
TWI705814B (zh) 2020-10-01
HUE044764T2 (hu) 2019-11-28
CA2952950C (en) 2023-11-14
DK3581180T3 (da) 2021-11-08
TW201625249A (zh) 2016-07-16
CL2020003153A1 (es) 2021-06-25
CL2016003273A1 (es) 2017-08-04
ES2897576T3 (es) 2022-03-01
PH12022550979A1 (en) 2023-06-26
HRP20211685T1 (hr) 2022-02-04
CY1121995T1 (el) 2020-10-14
AU2021286284A1 (en) 2022-01-06
EA201692532A1 (ru) 2017-05-31
RS62538B1 (sr) 2021-12-31
ECSP16095540A (es) 2017-03-31
DK3157510T3 (da) 2019-07-01
CN114831955B (zh) 2024-03-12
BR112016029761A2 (pt) 2017-08-22
EA034152B1 (ru) 2020-01-09
TWI732337B (zh) 2021-07-01
CN106572982B9 (zh) 2022-07-08
CN106572982A (zh) 2017-04-19
WO2015196027A1 (en) 2015-12-23
JP7149991B2 (ja) 2022-10-07
MX2019012608A (es) 2019-12-02
BR112016029761B1 (pt) 2023-03-07
MX368940B (es) 2019-10-21
CN106572982B (zh) 2022-06-03
SV2016005349A (es) 2017-08-31
US20200237744A1 (en) 2020-07-30
US20150366857A1 (en) 2015-12-24
PE20210927A1 (es) 2021-05-19
MX2016017350A (es) 2017-04-06
PH12016502548B1 (en) 2023-05-24
EP3581180B1 (en) 2021-08-04
EP3157510A4 (en) 2018-02-21
ES2732865T3 (es) 2019-11-26
SI3157510T1 (sl) 2019-09-30
LT3157510T (lt) 2019-09-25
EP3157510A1 (en) 2017-04-26
SMT202100618T1 (it) 2022-01-10
CN114831955A (zh) 2022-08-02
LT3581180T (lt) 2021-12-27
TW202005650A (zh) 2020-02-01
EP3919057A1 (en) 2021-12-08
JP6995479B2 (ja) 2022-01-14
PE20170304A1 (es) 2017-04-19
EP3581180A1 (en) 2019-12-18
PT3581180T (pt) 2021-11-09
AU2020256457A1 (en) 2020-11-12
PT3157510T (pt) 2019-06-21
PL3581180T3 (pl) 2022-02-07
IL249622A0 (en) 2017-02-28
EP3157510B1 (en) 2019-03-27
JP2020183415A (ja) 2020-11-12
CR20200565A (es) 2021-01-14
AU2015276954B2 (en) 2020-07-23
UY36184A (es) 2016-01-29
JP2017518349A (ja) 2017-07-06
RS59064B1 (sr) 2019-08-30
SI3581180T1 (sl) 2021-12-31

Similar Documents

Publication Publication Date Title
CY1125193T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν μελοξικαμη
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1122142T1 (el) Συνθεσεις που περιλαμβανουν στελεχη του βακτηριου blautia για τη θεραπευτικη αγωγη σπλαγχνικης υπερευαισθησιας
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
EA201691421A1 (ru) Гетероарилы и их применение
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
CY1120490T1 (el) Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CY1124967T1 (el) Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1121171T1 (el) Πυρογλουταμικη βορτιοξετινη
EP3868385A4 (en) GASTRIC CANCER TREATMENT COMPOSITION INCLUDING A SYT11 INHIBITOR AS AN ACTIVE INGREDIENT
BR112018074985A2 (pt) composições antibacterianas
CY1125395T1 (el) Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες
MA54095A (fr) Formulations pharmaceutiques aqueuses
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний